The PE Ratio as of December 2024 (TTM) for Relmada Therapeutics, Inc. (RLMD) is -0.13

According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.13. This represents a change of -90.28% compared to the average of -1.34 of the last 4 quarters.

Relmada Therapeutics, Inc. (RLMD) Historical PE Ratio (quarterly & annually)

How has RLMD PE Ratio performed in the past?

The mean historical PE Ratio of Relmada Therapeutics, Inc. over the last ten years is -5.68. The current -0.13 PE Ratio has changed 128.69% with respect to the historical average. Over the past ten years (40 quarters), RLMD's PE Ratio was at its highest in in the December 2014 quarter at 7.21. The PE Ratio was at its lowest in in the December 2019 quarter at -24.49.

Relmada Therapeutics, Inc. (RLMD) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Relmada Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relmada Therapeutics, Inc. (RLMD) Average PE Ratio

How has RLMD PE Ratio performed in the past?

The current PE Ratio of Relmada Therapeutics, Inc. (RLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Relmada Therapeutics, Inc. (RLMD) PE Ratio vs. Peers

How is RLMD’s PE Ratio compared to its peers?

Relmada Therapeutics, Inc.’s PE Ratio is greater than Cytokinetics, Incorporated (-9.91), greater than DICE Therapeutics, Inc. (-22.94), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Karuna Therapeutics, Inc. (-37.08), greater than Dyne Therapeutics, Inc. (-8.21), greater than Third Harmonic Bio, Inc. (-10.88), greater than PMV Pharmaceuticals, Inc. (-1.47), greater than Enochian Biosciences, Inc. (-1.98), greater than Revolution Medicines, Inc. (-13.06), greater than Pardes Biosciences, Inc. (-1.36), greater than Shattuck Labs, Inc. (-0.76), less than Eliem Therapeutics, Inc. (0), greater than Champions Oncology, Inc. (-178.90), greater than Century Therapeutics, Inc. (-0.67), greater than Fusion Pharmaceuticals Inc. (-17.31), greater than Bicycle Therapeutics plc (-6.09), greater than RAPT Therapeutics, Inc. (-0.63), greater than NewAmsterdam Pharma Company N.V. (-13.47), greater than Cyteir Therapeutics, Inc. (-9.12), greater than Nuvation Bio Inc. (-1.45), greater than Magenta Therapeutics, Inc. (-0.15), greater than Neoleukin Therapeutics, Inc. (-5.86), less than Graphite Bio, Inc. (-0.13),

Build a custom stock screener for Relmada Therapeutics, Inc. (RLMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relmada Therapeutics, Inc. (RLMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.